@article{StangeDesirKakaretal.2015,
  author    = {Stange, Katja and D{\´e}sir, Julie and Kakar, Naseebullah and Mueller, Thomas D. and Budde, Birgit S. and Gordon, Christopher T. and Horn, Denise and Seemann, Petra and Borck, Guntram},
  title     = {A hypomorphic BMPR1B mutation causes du Pan acromesomelic dysplasia},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {10},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {84},
  doi       = {10.1186/s13023-015-0299-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-151650},
  year      = {2015},
  abstract  = {Background: Grebe dysplasia, Hunter-Thompson dysplasia, and du Pan dysplasia constitute a spectrum of skeletal dysplasias inherited as an autosomal recessive trait characterized by short stature, severe acromesomelic shortening of the limbs, and normal axial skeleton. The majority of patients with these disorders have biallelic loss-of-function mutations of GDF5. In single instances, Grebe dysplasia and a Grebe dysplasia-like phenotype with genital anomalies have been shown to be caused by mutations in BMPR1B, encoding a GDF5 receptor. Methods: We clinically and radiologically characterised an acromesomelic chondrodysplasia in an adult woman born to consanguineous parents. We sequenced GDF5 and BMPR1B on DNA of the proposita. We performed 3D structural analysis and luciferase reporter assays to functionally investigate the identified BMPR1B mutation. Results: We extend the genotype-phenotype correlation in the acromesomelic chondrodysplasias by showing that the milder du Pan dysplasia can be caused by a hypomorphic BMPR1B mutation. We show that the homozygous c.91C>T, p.(Arg31Cys) mutation causing du Pan dysplasia leads to a significant loss of BMPR1B function, but to a lesser extent than the previously reported p.Cys53Arg mutation that results in the more severe Grebe dysplasia. Conclusions: The phenotypic severity gradient of the clinically and radiologically related acromesomelic chondrodysplasia spectrum of skeletal disorders may be due to the extent of functional impairment of the ligand-receptor pair GDF5-BMPR1B.},
  language  = {en}
}
@article{EmmerichMurawskiEhmenetal.2021,
  author    = {Emmerich, Petra and Murawski, Carolin and Ehmen, Christa and von Possel, Ronald and Pekarek, Neele and Oestereich, Lisa and Duraffour, Sophie and Pahlmann, Meike and Struck, Nicole and Eibach, Daniel and Krumkamp, Ralf and Amuasi, John and Maiga-Ascofar{\´e}, Oumou and Rakotozandrindrainy, Raphael and Asogun, Danny and Ighodalo, Yemisi and Kann, Simone and May, J{\"u}rgen and Tannich, Egbert and Deschermeier, Christina},
  title     = {Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin},
  series = {Tropical Medicine \& International Health},
  volume    = {26},
  journal   = {Tropical Medicine \& International Health},
  number    = {6},
  doi       = {10.1111/tmi.13569},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239899},
  pages     = {621 -- 631},
  year      = {2021},
  abstract  = {Objectives Specific serological tests are mandatory for reliable SARS-CoV-2 diagnostics and seroprevalence studies. Here, we assess the specificities of four commercially available SARS-CoV-2 IgG ELISAs in serum/plasma panels originating from Africa, South America, and Europe. Methods 882 serum/plasma samples collected from symptom-free donors before the COVID-19 pandemic in three African countries (Ghana, Madagascar, Nigeria), Colombia, and Germany were analysed with three nucleocapsid-based ELISAs (Euroimmun Anti-SARS-CoV-2-NCP IgG, EDI™ Novel Coronavirus COVID-19 IgG, Mikrogen recomWell SARS-CoV-2 IgG), one spike/S1-based ELISA (Euroimmun Anti-SARS-CoV-2 IgG), and in-house common cold CoV ELISAs. Results High specificity was confirmed for all SARS-CoV-2 IgG ELISAs for Madagascan (93.4-99.4\%), Colombian (97.8-100.0\%), and German (95.9-100.0\%) samples. In contrast, specificity was much lower for the Ghanaian and Nigerian serum panels (Ghana: NCP-based assays 77.7-89.7\%, spike/S1-based assay 94.3\%; Nigeria: NCP-based assays 39.3-82.7\%, spike/S1-based assay 90.7\%). 15 of 600 African sera were concordantly classified as positive in both the NCP-based and the spike/S1-based Euroimmun ELISA, but did not inhibit spike/ACE2 binding in a surrogate virus neutralisation test. IgG antibodies elicited by previous infections with common cold CoVs were found in all sample panels, including those from Madagascar, Colombia, and Germany and thus do not inevitably hamper assay specificity. Nevertheless, high levels of IgG antibodies interacting with OC43 NCP were found in all 15 SARS-CoV-2 NCP/spike/S1 ELISA positive sera. Conclusions Depending on the chosen antigen and assay protocol, SARS-CoV-2 IgG ELISA specificity may be significantly reduced in certain populations probably due to interference of immune responses to endemic pathogens like other viruses or parasites.},
  language  = {en}
}
@article{ElMoualiGerovacMineikaitėetal.2021,
  author    = {El Mouali, Youssef and Gerovac, Milan and Mineikaitė, Raminta and Vogel, J{\"o}rg},
  title     = {In vivo targets of Salmonella FinO include a FinP-like small RNA controlling copy number of a cohabitating plasmid},
  series = {Nucleic Acids Research},
  volume    = {49},
  journal   = {Nucleic Acids Research},
  number    = {9},
  doi       = {10.1093/nar/gkab281},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-261072},
  pages     = {5319-5335},
  year      = {2021},
  abstract  = {FinO-domain proteins represent an emerging family of RNA-binding proteins (RBPs) with diverse roles in bacterial post-transcriptional control and physiology. They exhibit an intriguing targeting spectrum, ranging from an assumed single RNA pair (FinP/traJ) for the plasmid-encoded FinO protein, to transcriptome-wide activity as documented for chromosomally encoded ProQ proteins. Thus, the shared FinO domain might bear an unusual plasticity enabling it to act either selectively or promiscuously on the same cellular RNA pool. One caveat to this model is that the full suite of in vivo targets of the assumedly highly selective FinO protein is unknown. Here, we have extensively profiled cellular transcripts associated with the virulence plasmid-encoded FinO in Salmonella enterica. While our analysis confirms the FinP sRNA of plasmid pSLT as the primary FinO target, we identify a second major ligand: the RepX sRNA of the unrelated antibiotic resistance plasmid pRSF1010. FinP and RepX are strikingly similar in length and structure, but not in primary sequence, and so may provide clues to understanding the high selectivity of FinO-RNA interactions. Moreover, we observe that the FinO RBP encoded on the Salmonella virulence plasmid controls the replication of a cohabitating antibiotic resistance plasmid, suggesting cross-regulation of plasmids on the RNA level.},
  language  = {en}
}